<a href="https://laohu8.com/S/ALVO">Alvotech</a> and Advanz Pharma Secure EC Approval for Gobivaz Biosimilar to Simponi
Alvotech SA and Advanz Pharma have announced that the European Commission has granted marketing authorization for Gobivaz®, Alvotech's biosimilar to Simponi® (golimumab), across the European Economic Area $(EEA)$. Gobivaz® is the first biosimilar to Simponi® approved in Europe and will be available in multiple formulations for the treatment of several immune-mediated diseases, including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, and juvenile idiopathic arthritis. Under the partnership, Alvotech is responsible for development and supply, while Advanz Pharma holds exclusive commercialization rights in the EEA and UK. This approval follows a positive opinion from the EMA's Committee for Medicinal Products for Human Use.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001139966-en) on November 20, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。